Teva Pharmaceuticals

1622 articles with Teva Pharmaceuticals

• Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea

  6/16/2021

  Teva Pharmaceuticals today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.

• 

  Lilly Launches Head-to-Head Trial in Quest to Bolster Migraine Preventive Drug 

  6/15/2021

  Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine. 

• Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine

  6/3/2021

  Teva to Present Latest Data on AJOVY ® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine 11 presentations examine clinical and real-world AJOVY data in the reduction of migraine days

• Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

  5/17/2021

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available generic version, in the U.S., of THIOLA® (tiopronin) tablets, indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine (kidney) stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria

• Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference

  5/10/2021

  Two e-posters include new data across asthma and chronic obstructive pulmonary disease (COPD), emphasizing Teva’s commitment to patients with respiratory diseases

• Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

  5/5/2021

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.

• Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States

  5/4/2021

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals.

• Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting

  5/3/2021

  Teva to Present New Long-Term AUSTEDO ® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks

• Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States

  4/29/2021

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater.

• Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting

  4/27/2021

  Teva to Present New Analyses of AUSTEDO ® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting Four posters examine the long-term efficacy, safety, and tolerability of AUSTEDO in patients with tardive dyskinesia and a review of clinical outcome measures in schizophrenia

• Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States

  4/23/2021

  Teva Announces Launch of its Generic Version of Canasa ® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States

• 

  CEO Salaries for the Top 20 Pharma Companies by Market Cap

  4/23/2021

  Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...

• Teva Canada Welcomes Efforts to Address Critical Drug Supply in the Federal Budget

  4/20/2021

  Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., strongly welcomes the Government of Canada's commitment in the April 19, 2021 federal budget to support Canada's life science sector.

• 

  J&J, Teva and Other Opioid Drugmakers Face $50 Billion Lawsuit in California

  4/19/2021

  Johnson & Johnson, Endo International, AbbVie’s Allergan unit and Teva Pharmaceutical will head to court this morning in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.

• Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting

  4/15/2021

  Teva to Present New Analyses of AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s Ongoing Commitment to Neurology

• Frontier Pharma and Baystone Group completes its acquisition of Zdravlje, a high quality pharmaceutical manufacturer in Serbia

  4/1/2021

  Zdravlje represents a solid foundation upon which a leading international pharmaceutical platform will be built over the coming years

• Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States

  3/8/2021

  Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT ®

• Teva Reports Fourth Quarter and Full Year 2020 Financial Results

  2/10/2021

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020.

• Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

  1/14/2021

  Teva Announces Launch of a Generic Version of NuvaRing ® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

• Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance at 8 a.m. ET on February 10, 2021

  1/8/2021

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the fol